Novartis has confirmed it is planning to reduce its headcount as part of a restructuring initiative announced last week, but has declined to put a figure on the cuts, as various media outle
Pfizer reckons it will make a whopping $22 billion in sales of its oral COVID-19 antiviral Paxlovid in 2022, with another $32 billion from its BioNTech-partnered coronavirus vaccine Comirna
The FDA has limited the use of COVID-19 antibody therapies developed by Eli Lilly and Regeneron, on the back of data suggesting they have are "highly unlikely" to be effective against the n
Regeneron has enlisted the aid of Ultragenyx to add momentum to the rollout of its recently-approved Evkeeza outside the US, which was approved for an inherited form of elevated cholesterol
Shares in France's Valneva leaped after it got an EU order to supply 60 million doses of its COVID-19 vaccine VLA2001 over the next two years, including 27 million next year.
The US federal government has ordered another 1.4 million doses of Merck & Co and Ridgeback Biotherapeutics' oral antiviral molnupiravir for COVID-19, adding to an earlier agreement to